Why Regado Biosciences (RGDO) Stock Is Plummeting Today

NEW YORK (TheStreet) -- Regado Biosciences (RGDO) shares are cratering, down over 50% to $2.94, on Thursday after the Data Safety Monitoring Board recommended that patients in the company's REGULATE-PCI drug trial stop being dosed due to allergic reactions following an unplanned review of the trials.

The company announced that patient enrollment for the blood clot treatment trials will be halted until the review, which is expected to take a couple of months, is completed.

Must ReadWarren Buffett's 25 Favorite Stocks

RGDO Chart

RGDO data by YCharts

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers